Patent ID: 8470781

Claim:
A method for inhibiting the conversion of a N-terminal glutamic acid or glutamine residue to a pyroglutamic acid residue of at least one substrate of glutaminyl cyclase in a mammalian subject comprising: administering to a mammalian subject in need thereof a therapeutically effective amount of an inhibitor of glutaminyl cyclase (QC), wherein, the QC inhibitor has the general formula 1: including all pharmaceutically acceptable salts and stereoisomers thereof, R 1 -R 6 are independently H or a branched or unbranched alkyl chain, a branched or unbranched alkenyl chain, a branched or unbranched alkynyl chain, carbocyclic, aryl, heteroaryl, heterocyclic, aza-amino acid, amino acid or a mimetic thereof, peptide or a mimetic thereof; the branched or unbranched alkyl chain, branched or unbranched alkenyl chain, branched or unbranched alkynyl chain, carbocyclic, aryl, heteroaryl, heterocyclic, aza-amino acid, amino acid or mimetic thereof, peptide or mimetic thereof of R 1 -R 6 being optionally substituted; and n can be 0, 1 or 2; and the at least one substrate of glutaminyl cyclase is selected from the group consisting of Glu 1 -ADan, Glu 1 -ABri, [Gln 3 ]Aβ(3-11)a, Aβ3-40/42, Aβ11-40/42, [Gln 3 ]Aβ3-40/42, and [Gln 1 ]Fractalkine.